Allergic rhinitis (AR) and chronic rhinosinusitis (CRS) are two prevalent nasal diseases where both type 2 inflammation and immunoglobulin E (IgE) may play important roles. Although they can exist independently or comorbidly, subtle but important differences exist in immunopathogenesis.
Objective
To summarize current knowledge of pathophysiological roles of B lineage cells and IgE in AR and CRS with nasal polyps (CRSwNP).
Methods
Searched PubMed database, reviewed AR and CRSwNP-related literature, and discussed disease diagnosis, comorbidity, epidemiology, pathophysiology, and treatment. Similarities and differences in B-cell biology and IgE are compared in the 2 conditions.
Results
Both AR and CRSwNP have evidence for pathological type 2 inflammation, B-cell activation and differentiation, and IgE production. However, distinctions exist in the clinical and serological profiles at diagnosis, as well as treatments utilized. B-cell activation in AR may more frequently be regulated in the germinal center of lymphoid follicles, whereas CRSwNP may occur via extrafollicular pathways although controversies remain in these initial activating events. Oligoclonal and antigen-specific IgE maybe predominate in AR, but polyclonal and antigen-nonspecific IgE may predominate in CRSwNP. Omalizumab has been shown efficacious in treating both AR and CRSwNP in multiple clinical trials but is the only Food and Drug Administration-approved anti-IgE biologic to treat CRSwNP or allergic asthma. Staphylococcus aureus frequently colonizes the nasal airway and has the ability to activate type two responses including B-cell responses although the extent to which it modulates AR and CRSwNP disease severity is being investigated.
Conclusion
This review highlights current knowledge of the roles of B cells and IgE in the pathogenesis of AR and CRSwNP and a small comparison between the 2 diseases. More systemic studies should be done to elevate the understanding of these diseases and their treatment.
DykewiczMSWallaceDVAmrolDJ, et al.Rhinitis 2020: a practice parameter update. J Allergy Clin Immunol. 2020;146(4):721–767.
2.
GómezECampoPRondónC, et al.Role of the basophil activation test in the diagnosis of local allergic rhinitis. J Allergy Clin Immunol. 2013;132(4):975–976.e1-5.
3.
AsherMIMontefortSBjörksténB, et al.Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC phases one and three repeat multicountry cross-sectional surveys. Lancet. 2006;368(9537):733–743.
4.
RalstonSHPenmanIDStrachanMWJHobsonR (eds). Davidson's Principles and Practice of Medicine. 23rd ed.London, England: Elsevier Health Sciences, 2018.
5.
BousquetJAntoJMBachertC, et al.Allergic rhinitis. Nat Rev Dis Primers. 2020;6(1):95.
BousquetJKhaltaevNCruzAA, et al.Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63(Suppl 86):8–160.
8.
NorthMLJonesMJMacIsaacJL, et al.Blood and nasal epigenetics correlate with allergic rhinitis symptom development in the environmental exposure unit. Allergy. 2018;73(1):196–205.
9.
QiCJiangYYangIV, et al.Nasal DNA methylation profiling of asthma and rhinitis. J Allergy Clin Immunol. 2020;145(6):1655–1663.
10.
TanBKKlinglerAIPoposkiJA, et al.Heterogeneous inflammatory patterns in chronic rhinosinusitis without nasal polyps in Chicago, Illinois. J Allergy Clin Immunol. 2017;139(2):699–703.e7.
11.
SchleimerRP. Immunopathogenesis of chronic rhinosinusitis and nasal polyposis. Annu Rev Pathol. 2017;12(1):331–357.
12.
OrlandiRRKingdomTTSmithTL, et al.International consensus statement on allergy and rhinology: rhinosinusitis 2021. Int Forum Allergy Rhinol. 2021;11(3):213–739.
13.
WangXZhangNBoM, et al.Diversity of T(H) cytokine profiles in patients with chronic rhinosinusitis: a multicenter study in Europe, Asia, and Oceania. J Allergy Clin Immunol. 2016;138(5):1344–1353.
14.
BachertCMarpleBSchlosserRJ, et al.Adult chronic rhinosinusitis. Nat Rev Dis Primers. 2020;6(1):86.
15.
BenjaminMRStevensWWLiN, et al.Clinical characteristics of patients with chronic rhinosinusitis without nasal polyps in an academic setting. J Allergy Clin Immunol Pract. 2019;7(3):1010–1016.
TanBKKernRCSchleimerRPSchwartzBS. Chronic rhinosinusitis: the unrecognized epidemic. Am J Respir Crit Care Med. 2013;188(11):1275–1277.
18.
DeCondeASSolerZM. Chronic rhinosinusitis: epidemiology and burden of disease. Am J Rhinol Allergy. 2016;30(2):134–139.
19.
TanBKChandraRKPollakJ, et al.Incidence and associated premorbid diagnoses of patients with chronic rhinosinusitis. J Allergy Clin Immunol. 2013;131(5):1350–1360.
20.
John StaniorskiCPriceCPEWeibmanAR, et al.Asthma onset pattern and patient outcomes in a chronic rhinosinusitis population. Int Forum Allergy Rhinol. 2018;8(4):495–503.
21.
BrożekJLBousquetJAgacheI, et al.Allergic rhinitis and its impact on asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol. 2017;140(4):950–958.
TanBKZirkleWChandraRK, et al.Atopic profile of patients failing medical therapy for chronic rhinosinusitis. Int Forum Allergy Rhinol. 2011;1(2):88–94.
24.
PearlmanANChandraRKChangD, et al.Relationships between severity of chronic rhinosinusitis and nasal polyposis, asthma, and atopy. Am J Rhinol Allergy. 2009;23(2):145–148.
25.
LiQCChengKJWangFZhouSH. Role of atopy in chronic rhinosinusitis with nasal polyps: does an atopic condition affect the severity and recurrence of disease?J Laryngol Otol. 2016;130(7):640–644.
26.
SellaGCPTamashiroESellaJA, et al.Asthma is the dominant factor for recurrence in chronic rhinosinusitis. J Allergy Clin Immunol Pract. 2020;8(1):302–309.
27.
SmithKAOrlandiRROakleyGMeeksHCurtinKAltJA. Long-term revision rates for endoscopic sinus surgery. Int Forum Allergy Rhinol. 2019;9(4):402–408.
28.
HeJSNarayananSSubramaniamSHoWQLafailleJJCurotto de LafailleMA. Biology of IgE production: IgE cell differentiation and the memory of IgE responses. Curr Top Microbiol Immunol. 2015;388:1–19.
29.
Ebina-ShibuyaRLeonardWJ. Role of thymic stromal lymphopoietin in allergy and beyond. Nat Rev Immunol. 2022;2022:1–14.
30.
AkdisMVerhagenJTaylorA, et al.Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J Exp Med. 2004;199(11):1567–1575.
31.
HammadHLambrechtBN. Barrier epithelial cells and the control of type 2 immunity. Immunity. 2015;43(1):29–40.
32.
ShamjiMHValentaRJardetzkyT, et al.The role of allergen-specific IgE, IgG and IgA in allergic disease. Allergy. 2021;76(12):3627–3641.
33.
YaoYWangNChenCL, et al.CD23 Expression on switched memory B cells bridges T-B cell interaction in allergic rhinitis. Allergy. 2020;75(10):2599–2612.
34.
WheatleyLMTogiasA. Clinical practice. Allergic rhinitis. N Engl J Med. 2015;372(5):456–463.
35.
CokerHADurhamSRGouldHJ. Local somatic hypermutation and class switch recombination in the nasal mucosa of allergic rhinitis patients. J Immunol. 2003;171(10):5602–5610.
36.
HoofISchultenVLayhadiJA, et al.Allergen-specific IgG+ memory B cells are temporally linked to IgE memory responses. J Allergy Clin Immunol.2020;146(1):180–191.
37.
KleinJanAVinkeJSeverijnenLFokkensW. Local production and detection of (specific) IgE in nasal B-cells and plasma cells of allergic rhinitis patients. Eur Respir J.2000;15(3):491–497.
38.
TianGXPengKPLiuMH, et al.CD38(+) B cells affect immunotherapy for allergic rhinitis. J Allergy Clin Immunol. 2022;149(5):1691–1701.e9.
39.
KimASDohertyTAKartaMR, et al.Regulatory B cells and T follicular helper cells are reduced in allergic rhinitis. J Allergy Clin Immunol. 2016;138(4):1192–1195.e5.
40.
KamekuraRShigeharaKMiyajimaS, et al.Alteration of circulating type 2 follicular helper T cells and regulatory B cells underlies the comorbid association of allergic rhinitis with bronchial asthma. Clin Immunol.2015;158(2):204–211.
41.
PoposkiJAKlinglerAITanBK, et al.Group 2 innate lymphoid cells are elevated and activated in chronic rhinosinusitis with nasal polyps. Immun Inflamm Dis. 2017;5(3):233–243.
42.
KatoA. Group 2 innate lymphoid cells in airway diseases. Chest. 2019;156(1):141–149.
43.
WuY-CBJamesLKVander HeidenJA, et al.Influence of seasonal exposure to grass pollen on local and peripheral blood IgE repertoires in patients with allergic rhinitis. J Allergy Clin Immunol.2014;134(3):604–612.
44.
De SchryverEDevuystLDeryckeL, et al.Local immunoglobulin E in the nasal mucosa: clinical implications. Allergy Asthma Immunol Res. 2015;7(4):321–331.
45.
AllenCDC. Features of B cell responses relevant to allergic disease. J Immunol. 2022;208(2):257–266.
46.
TanBKLiQZSuhL, et al.Evidence for intranasal antinuclear autoantibodies in patients with chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2011;128(6):1198–1206.e1.
47.
GevaertPNouri-AriaKTWuH, et al.Local receptor revision and class switching to IgE in chronic rhinosinusitis with nasal polyps. Allergy. 2013;68(1):55–63.
48.
HulseKENortonJESuhL, et al.Chronic rhinosinusitis with nasal polyps is characterized by B-cell inflammation and EBV-induced protein 2 expression. J Allergy Clin Immunol. 2013;131(4):1075–1083.e1-7.
49.
TsybikovNNEgorovaEVKuznikBIFefelovaEVMagenE. Anticytokine autoantibodies in chronic rhinosinusitis. Allergy Asthma Proc. 2015;36(6):473–480.
50.
FeldmanSKasjanskiRPoposkiJ, et al.Chronic airway inflammation provides a unique environment for B cell activation and antibody production. Clin Exp Allergy. 2017;47(4):457–466.
51.
BaiJHulseKEHuangJHSchleimerRPTanBK. Anti-dsDNA specific antibody secreting cells are increased in both frequency and abundance in chronic rhinosinusitis with nasal polyps. J Immunol. 2020;204(Abstr.).
52.
BuchheitKMDwyerDFOrdovas-MontanesJ, et al.IL-5Rα marks nasal polyp IgG4- and IgE-expressing cells in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2020;145(6):1574–1584.
53.
De SchryverECalusLBonteH, et al.The quest for autoreactive antibodies in nasal polyps. J Allergy Clin Immunol. 2016;138(3):893–895.e5.
54.
CorradoARamonellRPWoodruffMC, et al.Extrafollicular IgD+ B cells generate IgE antibody secreting cells in the nasal mucosa. Mucosal Immunol.2021;14(5):1144–1159.
55.
BachertCMaurerMPalomaresOBusseWW. What is the contribution of IgE to nasal polyposis?J Allergy Clin Immunol.2021:1997–2008.
56.
BaiJHuangJHPriceCPE, et al.Prognostic factors for polyp recurrence in chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2022;149(2):AB143.
57.
ZhangYNSongJWangH, et al.Nasal IL-4(+)CXCR5(+)CD4(+) T follicular helper cell counts correlate with local IgE production in eosinophilic nasal polyps. J Allergy Clin Immunol. 2016;137(2):462–473.
58.
LauALesterSMoraitisS, et al.Tertiary lymphoid organs in recalcitrant chronic rhinosinusitis. J Allergy Clin Immunol. 2017;139(4):1371–1373.e6.
59.
PereiraJPKellyLMXuYCysterJG. EBI2 mediates B cell segregation between the outer and centre follicle. Nature. 2009;460(7259):1122–1126.
60.
GattoDBrinkR. B cell localization: regulation by EBI2 and its oxysterol ligand. Trends Immunol. 2013;34(7):336–341.
61.
GattoDPausDBastenAMackayCRBrinkR. Guidance of B cells by the orphan G protein-coupled receptor EBI2 shapes humoral immune responses. Immunity. 2009;31(2):259–269.
62.
ChanTDGardamSGattoDTurnerVMSilkeJBrinkR. In vivo control of B-cell survival and antigen-specific B-cell responses. Immunol Rev. 2010;237(1):90–103.
63.
GattoDWoodKBrinkR. EBI2 operates independently of but in cooperation with CXCR5 and CCR7 to direct B cell migration and organization in follicles and the germinal center. J Immunol. 2011;187(9):4621–4628.
64.
PereiraJPKellyLMCysterJG. Finding the right niche: B-cell migration in the early phases of T-dependent antibody responses. Int Immunol. 2010;22(6):413–419.
65.
Van ZeleTClaeysSGevaertP, et al.Differentiation of chronic sinus diseases by measurement of inflammatory mediators. Allergy. 2006;61(11):1280–1289.
66.
CysterJGAllenCDC. B cell responses: cell interaction dynamics and decisions. Cell. 2019;177(3):524–540.
67.
JenksSACashmanKSWoodruffMCLeeFESanzI. Extrafollicular responses in humans and SLE. Immunol Rev. 2019;288(1):136–148.
68.
JeffeJSSeshadriSHamillKJ, et al.A role for anti-BP180 autoantibodies in chronic rhinosinusitis. Laryngoscope. 2013;123(9):2104–2111.
69.
Van RoeyGAVanisonCCWuJ, et al.Classical complement pathway activation in the nasal tissue of patients with chronic rhinosinusitis. J Allergy Clin Immunol. 2017;140(1):89–100.e2.
70.
KatoAPetersASuhL, et al.Evidence of a role for B cell-activating factor of the TNF family in the pathogenesis of chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2008;121(6):1385–1392.e1-2.
71.
ZhangFXuZHeXSunYZhaoCZhangJ. Increased B cell-activating factor expression is associated with postoperative recurrence of chronic rhinosinusitis with nasal polyps. Mediators Inflamm. 2022;2022:7338692.
72.
PetersATKatoAZhangN, et al.Evidence for altered activity of the IL-6 pathway in chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2010;125(2):397–403.e10.
73.
SmurthwaiteLDurhamSR. Local IgE synthesis in allergic rhinitis and asthma. Curr Allergy Asthma Rep.2002;2(3):231–238.
74.
CaoPPZhangYNLiaoB, et al.Increased local IgE production induced by common aeroallergens and phenotypic alteration of mast cells in Chinese eosinophilic, but not non-eosinophilic, chronic rhinosinusitis with nasal polyps. Clin Exp Allergy. 2014;44(5):690–700.
75.
BachertCGevaertPHoltappelsGJohanssonSGvan CauwenbergeP. Total and specific IgE in nasal polyps is related to local eosinophilic inflammation. J Allergy Clin Immunol. 2001;107(4):607–614.
76.
SheahanPAhnCNHarveyRJ, et al.Local IgE production in nonatopic nasal polyposis. J Otolaryngol Head Neck Surg. 2010;39(1):45–51.
77.
CuiXYMiaoJLLuHQ, et al.Serum levels of specific IgE to Staphylococcus aureus enterotoxins in patients with chronic rhinosinusitis. Exp Ther Med. 2015;9(4):1523–1527.
78.
MehrajJWitteWAkmatovMKLayerFWernerGKrauseG. Epidemiology of Staphylococcus aureus nasal carriage patterns in the community. Curr Top Microbiol Immunol. 2016;398:55–87.
79.
PastacaldiCLewisPHowarthP. Staphylococci and staphylococcal superantigens in asthma and rhinitis: a systematic review and meta-analysis. Allergy. 2011;66(4):549–555.
80.
Van ZeleTGevaertPWateletJ-B, et al.Staphylococcus aureus colonization and IgE antibody formation to enterotoxins is increased in nasal polyposis. J Allergy Clin Immunol.2004;114(4):981–983.
81.
LanFZhangNHoltappelsG, et al.Staphylococcus aureus induces a mucosal type 2 immune response via epithelial cell-derived cytokines. Am J Respir Crit Care Med. 2018;198(4):452–463.
82.
BachertCZhangNPatouJvan ZeleTGevaertP. Role of staphylococcal superantigens in upper airway disease. Curr Opin Allergy Clin Immunol. 2008;8(1):34–38.
83.
GrailleMSturaEACorperAL, et al.Crystal structure of a Staphylococcus aureus protein A domain complexed with the Fab fragment of a human IgM antibody: structural basis for recognition of B-cell receptors and superantigen activity. Proc Natl Acad Sci USA.2000;97(10):5399–5404.
84.
KristiansenSVPascualVLipskyPE. Staphylococcal protein A induces biased production of Ig by VH3-expressing B lymphocytes. J Immunol. 1994;153(7):2974–2982.
85.
ShiomoriTYoshidaS-iMiyamotoHMakishimaK. Relationship of nasal carriage of Staphylococcus aureus to pathogenesis of perennial allergic rhinitis. J Allergy Clin Immunol.2000;105(3):449–454.
86.
CalabreseCSecciaVPelaiaC, et al.S. aureus and IgE-mediated diseases: pilot or copilot? A narrative review. Expert Rev Clin Immunol.2022;18(6):639–647.
87.
OkanoMTakishitaTYamamotoT, et al.Presence and characterization of sensitization to staphylococcal enterotoxins in patients with allergic rhinitis. Am J Rhinol. 2001;15(6):417–421.
88.
RossiREMonasteroloG. Prevalence of serum IgE antibodies to the Staphylococcus aureus enterotoxins (SAE, SEB, SEC, SED, TSST-1) in patients with persistent allergic rhinitis. Int Arch Allergy Immunol. 2004;133(3):261–266.
89.
LiuJNShinYSYooHS, et al.The prevalence of serum specific IgE to superantigens in asthma and allergic rhinitis patients. Allergy Asthma Immunol Res. 2014;6(3):263–266.
90.
HeymansFFischerAStowNW, et al.Screening for staphylococcal superantigen genes shows no correlation with the presence or the severity of chronic rhinosinusitis and nasal polyposis. PLoS ONE. 2010;5(3):e9525.
RamakrishnanVRFeazelLMAbrassLJFrankDN. Prevalence and abundance of Staphylococcus aureus in the middle meatus of patients with chronic rhinosinusitis, nasal polyps, and asthma. Int Forum Allergy Rhinol. 2013;3(4):267–271.
93.
NiederfuhrAKirscheHDeutschleTPoppertSRiechelmannHWellinghausenN. Staphylococcus aureus in nasal lavage and biopsy of patients with chronic rhinosinusitis. Allergy. 2008;63(10):1359–1367.
94.
SeiberlingKAConleyDBTripathiA, et al.Superantigens and chronic rhinosinusitis: detection of staphylococcal exotoxins in nasal polyps. Laryngoscope. 2005;115(9):1580–1585.
95.
ZhangNHoltappelsGGevaertP, et al.Mucosal tissue polyclonal IgE is functional in response to allergen and SEB. Allergy. 2011;66(1):141–148.
96.
BachertCZhangNHoltappelsG, et al.Presence of IL-5 protein and IgE antibodies to staphylococcal enterotoxins in nasal polyps is associated with comorbid asthma. J Allergy Clin Immunol. 2010;126(5):962–968.e1-6.
97.
ChangSWParkJJHwangCS, et al.Role of specific IgE on staphylococcal enterotoxin B in chronic rhinosinusitis severity. Clin Otolaryngol. 2021;46(2):304–310.
98.
WangXZhangNBoM, et al.Diversity of TH cytokine profiles in patients with chronic rhinosinusitis: a multicenter study in Europe, Asia, and Oceania. J Allergy Clin Immunol.2016;138(5):1344–1353.
99.
KotoulasSCTsiouprouIFoukaEPatakaAPapakostaDPorpodisK. Omalizumab: an optimal choice for patients with severe allergic asthma. J Pers Med.2022;12(2):165.
100.
HideMParkHSIgarashiA, et al.Efficacy and safety of omalizumab in Japanese and Korean patients with refractory chronic spontaneous urticaria. J Dermatol Sci. 2017;87(1):70–78.
101.
GevaertPOmachiTACorrenJ, et al.Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J Allergy Clin Immunol. 2020;146(3):595–605.
102.
HanJKYooBSaenzRBraidJMilletteLALeeSE. Omalizumab and quality of life in nasal polyps: a post hoc analysis. Int Forum Allergy Rhinol. 2022;12(9):1188–1190.
103.
GevaertPSaenzRCorrenJ, et al.Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension study. J Allergy Clin Immunol. 2022;149(3):957–965.e3.
104.
El-QutobD. Off-Label uses of omalizumab. Clin Rev Allergy Immunol. 2016;50(1):84–96.
105.
PenningtonLFTarchevskayaSBriggerD, et al.Structural basis of omalizumab therapy and omalizumab-mediated IgE exchange. Nat Commun. 2016;7:11610.
106.
EggelABaravalleGHobiG, et al.Accelerated dissociation of IgE-FcεRI complexes by disruptive inhibitors actively desensitizes allergic effector cells. J Allergy Clin Immunol. 2014;133(6):1709–1719.e8.
107.
GasserPTarchevskayaSSGunternP, et al.The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab. Nat Commun. 2020;11(1):165.
108.
LinHBoeselKMGriffithDT, et al.Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils. J Allergy Clin Immunol. 2004;113(2):297–302.
109.
HolgateSBuhlRBousquetJSmithNPanahlooZJimenezP. The use of omalizumab in the treatment of severe allergic asthma: a clinical experience update. Respir Med. 2009;103(8):1098–1113.
110.
ChanMAGigliottiNMDotsonALRosenwasserLJ. Omalizumab may decrease IgE synthesis by targeting membrane IgE+ human B cells. Clin Transl Allergy. 2013;3(1):29.
111.
DjukanovićRWilsonSJKraftM, et al.Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med. 2004;170(6):583–593.
112.
MassanariMHolgateSTBusseWWJimenezPKianifardFZeldinR. Effect of omalizumab on peripheral blood eosinophilia in allergic asthma. Respir Med.2010;104(2):188–196.
113.
TsabouriSNtritsosGKoskeridisFEvangelouEOlssonPKostikasK. Omalizumab for the treatment of allergic rhinitis: a systematic review and meta-analysis. Rhinology. 2021;59(6):501–510.
114.
YuCWangKCuiX, et al.Clinical efficacy and safety of omalizumab in the treatment of allergic rhinitis: a systematic review and meta-analysis of randomized clinical trials. Am J Rhinol Allergy. 2020;34(2):196–208.
115.
ZhangYXiLGaoY, et al.Omalizumab is effective in the preseasonal treatment of seasonal allergic rhinitis. Clin Transl Allergy. 2022;12(1):e12094.
116.
GevaertPCalusLVan ZeleT, et al.Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol. 2013;131(1):110–116.e1.
117.
PetersATHanJKHellingsP, et al.Indirect treatment comparison of biologics in chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol Pract. 2021;9(6):2461–2471.e5.
118.
JonstamKSwansonBNMannentLP, et al.Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis. Allergy. 2019;74(4):743–752.
119.
NumataTNakayamaKUtsumiH, et al.Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis. BMC Pulm Med.2019;19(1):176.
